Additionally, PD-L1 expression on myeloid cells in ovarian cancer and melanoma patients correlated with the success of the therapy with either anti–PD-L1 alone or in combination with an anti–CTLA-4 (5). Here, CTLA4 is linked to ovarian cancer.